Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Camp, NJ; Madsen, MJ; Herranz, J; Rodriguez-Lescure, A; Ruiz, A; Martin, M; Bernard, PS.

Re-interpretation of PAM50 gene expression as quantitative tumor dimensions shows utility for clinical trials: application to prognosis and response to paclitaxel in breast cancer

BREAST CANCER RESEARCH AND TREATMENT. 2019; 175(1): 129-139 Nº de citas: 10 [doi:10.1007/s10549-018-05097-5]

Pascual, T; Martin, M; Fernandez-Martinez, A; Pare, L; Alba, E; Rodriguez-Lescure, A; Perrone, G; Cortes, J; Morales, S; Lluch, A; Urruticoechea, A; Gonzalez-Farre, B; Galvan, P; Jares, P; Rodriguez, A; Chic, N; Righi, D; Cejalvo, JM; Tonini, G; Adamo, B; Vidal, M; Villagrasa, P; Munoz, M; Prat, A.

A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer

Frontiers in Oncology. 2019; 9: Nº de citas: 9 [doi:10.3389/fonc.2019.00303]

Lebbe, C; Meyer, N; Mortier, L; Marquez-Rodas, I; Robert, C; Rutkowski, P; Menzies, AM; Eigentler, T; Ascierto, PA; Smylie, M; Schadendorf, D; Ajaz, M; Svane, IM; Gonzalez, R; Rollin, L; Lord-Bessen, J; Saci, A; Grigoryeva, E; Pigozzo, J.

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial

JOURNAL OF CLINICAL ONCOLOGY. 2019; 37(11): 867 Nº de citas: 293 [doi:10.1200/JCO.18.01998]

Delaloge, S; Cella, D; Ye, Y; Buyse, M; Chan, A; Barrios, CH; Holmes, FA; Mansi, J; Iwata, H; Ejlertsen, B; Moy, B; Chia, SKL; Gnant, M; Smichkoska, S; Ciceniene, A; Martinez, N; Filipovic, S; Ben-Baruch, NE; Joy, AA; Langkjer, ST; Senecal, F; de Boer, RH; Moran, S; Yao, B; Bryce, R; Auerbach, A; Fallowfield, L; Martin, M.

Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial

ANNALS OF ONCOLOGY. 2019; 30(4): 567-574 Nº de citas: 19 [doi:10.1093/annonc/mdz016]

Mendez, M; Torrente, M; Sanchez-Beato, M; Gonzalez-Rincon, J; Royuela, A; Gomez-Codina, J; de la Cruz-Merino, L; Rueda, A; Llanos, M; Quero, C; Rodriguez-Abreu, D; Guma, J; Monsalvo, S; Sabin, P; Provencio, M.

Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group

HEMATOLOGICAL ONCOLOGY. 2019; 37(2): 143-150 Nº de citas: 11 [doi:10.1002/hon.2601]

Chia, SKL; Martin, M; Holmes, FA; Ejlertsen, B; Delaloge, S; Moy, B; Iwata, H; von Minckwitz, G; Mansi, J; Barrios, CH; Gnant, M; Tomasevic, Z; Denduluri, N; Separovic, R; Kim, SB; Jakobsen, EH; Harvey, V; Robert, N; Smith, J; Harker, G; Zhang, B; Eli, LD; Ye, YN; Lalani, AS; Buyse, M; Chan, A.

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial

BREAST CANCER RESEARCH. 2019; 21: Nº de citas: 16 [doi:10.1186/s13058-019-1115-2]

Lope, V; Martin, M; Castello, A; Ruiz, A; Casas, AM; Baena-Canada, JM; Antolin, S; Ramos-Vazquez, M; Garcia-Saenz, JA; Munoz, M; Lluch, A; de Juan-Ferre, A; Jara, C; Sanchez-Rovira, P; Anton, A; Chacon, JI; Arcusa, A; Jimeno, MA; Bezares, S; Vioque, J; Carrasco, E; Perez-Gomez, B; Pollan, M.

Overeating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM study

Scientific Reports. 2019; 9: Nº de citas: 26 [doi:10.1038/s41598-019-39346-4]

Vidal, J; Bellosillo, B; Vivas, CS; Garcia-Alfonso, P; Carrato, A; Cano, MT; Garcia-Carbonero, R; Elez, E; Losa, F; Massuti, B; Valladares-Ayerbes, M; Vieitez, JM; Manzano, JL; Azuara, D; Gallego, J; Pairet, S; Capella, G; Salazar, R; Tabernero, J; Aranda, E; Montagut, C.

Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy

ANNALS OF ONCOLOGY. 2019; 30(3): 439-446 Nº de citas: 15 [doi:10.1093/annonc/mdz005]

Press, MF; Seoane, JA; Curtis, C; Quinaux, E; Guzman, R; Sauter, G; Eiermann, W; Mackey, JR; Robert, N; Pienkowski, T; Crown, J; Martin, M; Valero, V; Bee, V; Ma, YL; Villalobos, I; Slamon, DJ.

Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines

JAMA Oncology. 2019; 5(3): 366-375 Nº de citas: 25 [doi:10.1001/jamaoncol.2018.6012]

Borrero-Palacios, A; Cebrian, A; del Pulgar, MTG; Garcia-Carbonero, R; Garcia, P; Aranda, E; Elez, E; Lopez-Lopez, R; Cervantes, A; Valladares, M; Nadal, C; Vieitez, JM; Guillen-Ponce, C; Rodriguez, J; Hernandez, I; Garcia, JL; Vega-Bravo, R; Puime-Otin, A; Martinez-Useros, J; Del Puerto-Nevado, L; Rincon, R; Rodriguez-Remirez, M; Rojo, F; Garcia-Foncillas, J.

Combination of KIR2DS4 and Fc gamma RIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

Scientific Reports. 2019; 9: Nº de citas: 10 [doi:10.1038/s41598-019-39291-2]

Font, A; Luque, R; Villa, JC; Domenech, M; Vazquez, S; Gallardo, E; Virizuela, JA; Beato, C; Morales-Barrera, R; Gelabert, A; Macia, S; Puente, J; Rubio, G; Maldonado, X; Perez-Valderrama, B; Pinto, A; Calvo, OF; Grande, E; Garde-Noguera, J; Fernandez-Parra, E; Arranz, JA.

The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG)

TARGETED ONCOLOGY. 2019; 14(1): 15-32 Nº de citas: 11 [doi:10.1007/s11523-019-00619-7]

Ruiz-Borrego, M; Jimenez, B; Antolin, S; Garcia-Saenz, JA; Corral, J; Jerez, Y; Trigo, J; Urruticoechea, A; Colom, H; Gonzalo, N; Munoz, C; Benito, S; Caballero, R; Bezares, S; Carrasco, E; Rojo, F; Martin, M.

A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012-12 (EDALINE) study

INVESTIGATIONAL NEW DRUGS. 2019; 37(1): 98-108 Nº de citas: 45 [doi:10.1007/s10637-018-0614-9]

de Bono, JS; De Giorgi, U; Rodrigues, DN; Massard, C; Bracarda, S; Font, A; Arija, JAA; Shih, KC; Radavoi, GD; Xu, N; Chan, WY; Ma, H; Gendreau, S; Riisnaes, R; Patel, PH; Maslyar, DJ; Jinga, V.

Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss

CLINICAL CANCER RESEARCH. 2019; 25(3): 928-936 Nº de citas: 249 [doi:10.1158/1078-0432.CCR-18-0981]

Gorbunova, V; Beck, JT; Hofheinz, RD; Garcia-Alfonso, P; Nechaeva, M; Gracian, AC; Mangel, L; Fernandez, EE; Deming, DA; Ramanathan, RK; Torres, AH; Sullivan, D; Luo, Y; Berlin, JD.

A phase 2 randomised study of veliparib plus FOLFIRI +/- bevacizumab versus placebo plus FOLFIRI +/- bevacizumab in metastatic colorectal cancer

BRITISH JOURNAL OF CANCER. 2019; 120(2): 183-189 Nº de citas: 48 [doi:10.1038/s41416-018-0343-z]

Macarulla, T; Pazo-Cid, R; Guillen-Ponce, C; Lopez, R; Vera, R; Reboredo, M; Martin, AM; Rivera, F; Beveridge, RD; La Casta, A; Valades, JM; Martinez-Galan, J; Ales, I; Sastre, J; Perea, S; Hidalgo, M.

Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2

JOURNAL OF CLINICAL ONCOLOGY. 2019; 37(3): 230-238 Nº de citas: 74 [doi:10.1200/JCO.18.00089]

Johnston, S; Martin, M; Di Leo, A; Im, SA; Awada, A; Forrester, T; Frenzel, M; Hardebeck, MC; Cox, J; Barriga, S; Toi, M; Iwata, H; Goetz, MP.

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer

Npj Breast Cancer. 2019; 5: Nº de citas: 481 [doi:10.1038/s41523-018-0097-z]

Atrafi, F; Groen, HJM; Byers, LA; Garralda, E; Lolkema, MP; Sangha, RS; Viteri, S; Chae, YK; Camidge, DR; Gabrail, NY; Hu, BB; Tian, T; Nuthalapati, S; Hoening, E; He, L; Komarnitsky, P; Calles, A.

A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors

CLINICAL CANCER RESEARCH. 2019; 25(2): 496-505 Nº de citas: 40 [doi:10.1158/1078-0432.CCR-18-2014]

Yoshino, T; Portnoy, DC; Obermannova, R; Bodoky, G; Prausova, J; Garcia-Carbonero, R; Ciuleanu, T; Garcia-Alfonso, P; Cohn, AL; Van Cutsem, E; Yamazaki, K; Lonardi, S; Muro, K; Kim, TW; Yamaguchi, K; Grothey, A; O'Connor, J; Taieb, J; Wijayawardana, SR; Hozak, RR; Nasroulah, F; Tabernero, J.

Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study

ANNALS OF ONCOLOGY. 2019; 30(1): 124-131 Nº de citas: 52 [doi:10.1093/annonc/mdy461]